SoInMat™
Biomaterial Composite Design Platform
SoInMat™
Biomaterial Composite Design Platform
Predictive Design for Biomaterial Innovation.
Accelerating Translational Research from Lab to Clinic.
Integrating multi-physics simulation with AI performance prediction, SoInMat™ enables high-precision modeling of microsphere suspension, material degradation, and drug release behavior—transforming development from trial-and-error to intelligent design, reducing experimental workload by over 50%, and shortening IND submission timelines by more than one year.
-
Precision Simulation
Multi-physics coupling computation (CFD + FEA) simulates microsphere suspension and scaffold mechanical decay. -
Accelerated Translation
Shortens IND submission timelines by over one year, with experimental workload reduced by more than 50%. -
Interface Optimization
Predicts material-cell interactions to guide surface functionalization design. -
Clinical Validation
Supported PLLA microspheres through 240+ patient clinical enrollment (Class III medical device). -
Performance Prediction
Predicts degradation kinetics, mechanical strength, and drug release profiles. -
Technical Breakthrough
Dual decellularization process; ECM materials scheduled to initiate clinical-exemption registration in 2027.
SoInMat™
Biomaterial Composite Design Platform
SoInMat™
Biomaterial Composite Design Platform
Predictive Design for Biomaterial Innovation.
Accelerating Translational Research from Lab to Clinic.
Integrating multi-physics simulation with AI performance prediction, SoInMat™ enables high-precision modeling of microsphere suspension, material degradation, and drug release behavior—transforming development from trial-and-error to intelligent design, reducing experimental workload by over 50%, and shortening IND submission timelines by more than one year.
-
Precision Simulation
Multi-physics coupling computation (CFD + FEA) simulates microsphere suspension and scaffold mechanical decay. -
Accelerated Translation
Shortens IND submission timelines by over one year, with experimental workload reduced by more than 50%. -
Interface Optimization
Predicts material-cell interactions to guide surface functionalization design. -
Clinical Validation
Supported PLLA microspheres through 240+ patient clinical enrollment (Class III medical device). -
Performance Prediction
Predicts degradation kinetics, mechanical strength, and drug release profiles. -
Technical Breakthrough
Dual decellularization process; ECM materials scheduled to initiate clinical-exemption registration in 2027.
Intelligent Regenerative Biomaterials Pipeline
Intelligent Regenerative Biomaterials Pipeline
Project |
Indication |
Design Input |
Design Output |
Design Verification |
Design Validation |
Regulatory Submission |
Commercial Rights |
|---|---|---|---|---|---|---|---|
| Medical Devices > | |||||||
| APR-301Key Component | Recombinant Collagen, Sodium Hyaluronate | Non-Chronic Wounds and Surrounding Skin |
|
 |
||||
| APR-202Key Component | dECM | Endometrial Injury |
|
|
||||
| APR-102Key Component | dECM | Focal Cartilage Defects |
|
|
||||
| APR-101Key Component | PLLA Microspheres | Moderate-to-Severe Nasolabial Folds |
|
|
||||
| Drug-Device Combination Products > | |||||||
| APR-401Key Component | dECM, Stem Cells | Arthritis, Knee Joint Injury |
|
|
||||
SUNRAY R&D Pipeline
Medical Devices
-
APR-101
PLLA Poly-L-Lactic Acid Microspheres (Class III Medical Device)
Injectable PLLA microspheres stimulate autologous collagen regeneration to improve moderate-to-severe nasolabial folds, aiming to support natural and progressive facial rejuvenation.
Mechanism of Action
AI-assisted designed PLLA microspheres, injected into the deep dermis, continuously stimulate fibroblasts to produce collagen, with filler degradation and collagen regeneration kinetics matched, aiming to support natural restoration of tissue volume
Unmet Need
Conventional fillers primarily provide immediate physical volumization with relatively short duration; issues such as non-uniform particle size and inflammatory responses remain; limitations exist in achieving durable tissue regeneration
Current Status
Class III medical device clinical trial initiated in March 2026 across 6 sites, with Peking Union Medical College Hospital as the lead center; 248-patient enrollment completed in Q2 2026; full clinical follow-up expected to complete in Q4 2027
-
APR-201
dECM Cartilage Repair Scaffold (Class III Medical Device)
A decellularized extracellular matrix (dECM) cartilage repair scaffold, used in conjunction with microfracture surgery, aiming to promote regenerative repair of articular cartilage defects by mimicking the native cartilage microenvironment.
Mechanism of Action
The three-dimensional microstructure of the scaffold provides a niche for autologous mesenchymal stem cell adhesion, proliferation, and differentiation; retained growth factors such as TGF-β and BMP-2 promote directed differentiation of stem cells toward chondrocytes
Unmet Need
Fibrocartilage formed by conventional microfracture surgery has limitations in mechanical properties and durability; scaffold materials capable of inducing hyaline cartilage regeneration remain relatively lacking
Current Status
Pilot- and mid-scale production completed; scale-up production and animal studies are underway; clinical trial initiation expected in early 2027
-
APR-301
Recombinant Collagen Dressing (Class II Medical Device)
A sterile medical dressing composed of recombinant collagen lyophilized sponge and sodium hyaluronate solution, intended for the care of non-chronic wounds and surrounding skin.
Mechanism of Action
AI machine learning models intelligently match the recombinant collagen and sodium hyaluronate ratio, aiming to support synergistic efficacy. Personalized dressing formulations are dynamically generated based on different skin types and wound conditions
Unmet Need
Conventional dressings have relatively fixed formulations, with limitations in adapting to varying wound conditions; repair efficiency remains to be improved
Current Status
Medical device registration quality management system review and production license inspection have been completed; the registration supplement is currently under review; Class II medical device approval expected in June 2026
-
APR-401
ECM Endometrial Repair Material
A decellularized extracellular matrix (dECM) endometrial repair material, implanted via non-invasive instillation, aiming to support the repair of endometrial injury and the restoration of fertility.
Mechanism of Action
AI degradation kinetic models predict the scaffold's degradation rate within the uterine cavity, matching the natural endometrial repair cycle; non-invasive instillation ensures good retention while providing a cellular growth scaffold and bioactive signals
Unmet Need
Endometrial injury is one of the leading causes of female infertility, accounting for over 40% of cases. The efficacy of existing treatment options still has room for improvement; willingness for preventive treatment needs to be enhanced, and infertility rates remain high
Current Status
Pilot-, mid-scale, and scale-up production completed; pre-registration preparation underway; medical device registration submission expected in June 2026, with approval anticipated in Q4 2026
Regenerative Medicine Combination Products
-
APR-202
dECM Combined with Stem Cells for Knee Joint Repair (Drug-Device Combination Product)
dECM scaffold combined with autologous stem cells, aiming to mimic the physiological microenvironment of the knee joint and provide a "niche" for stem cells, exploring the potential for regenerative repair of degenerative joint disease.
Mechanism of Action
The AI-powered cell screening platform selects stem cell subpopulations with high differentiation potential and low tumorigenic risk; natural collagen, glycosaminoglycans, laminin, and growth factors in the ECM scaffold promote stem cell homing, adhesion, and differentiation
Unmet Need
Stem cell injection alone has limitations in retention rate and directed differentiation; conventional scaffolds have limitations in bioactive signaling. The potential of their synergistic intervention in degenerative joint disease is being explored
Current Status
Early-stage research, expected to complete in Q2 2026